Breaking News

Abzena Invests $5M to Boost Bioconjugate Development & Manufacturing

Aims to increase efficiencies at its Bristol, PA site in response to customer demand for bioconjugate development and cGMP manufacturing.

Author Image

By: Charlie Sternberg

Associate Editor

Abzena, an end-to-end integrated CDMO, has announced a $5 million expansion of its Bristol, PA bioconjugate development and cGMP manufacturing site.   The investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site’s existing bioconjugation capabilities and increases capacity to support the delivery of fully integrated biopharmaceutical drug programs. Meeting Increased Customer Demand This latest investment expands and optimizes the site&#8217...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters